Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Modern Rheumatology
Published in: Modern Rheumatology 6/2010

01-12-2010 | Case Report

Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis

Authors: Kayoko Kaneko, Toshihiro Nanki, Tadashi Hosoya, Fumitaka Mizoguchi, Nobuyuki Miyasaka

Published in: Modern Rheumatology | Issue 6/2010

Login to get access

Abstract

We present two patients with rheumatoid arthritis (RA) who developed necrotizing crescentic glomerulonephritis (NCGN) during etanercept therapy. Both patients developed proteinuria and hematuria, and one progressed to renal failure. Renal biopsy revealed NCGN. In both patients, nephritis improved following discontinuation of etanercept and administration of prednisolone. Physicians should be aware of etanercept-induced GN in patients with RA on anti-tumor necrosis factor therapy.
Literature
1.
Bongartz T, Sutton A, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.PubMedCrossRef
2.
Ehrenreich T, Churg J. Pathology of membranous nephropathy. In: Sommers SC, editor. Pathology annual. New York: Appleton-Century-Crofts; 1968. p. 145–86.
3.
Schwartz MM. Membranous glomerulonephritis. In: Jennette JC, Olson JL, Schwartz MM, Fred G, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 205–52.
4.
Messiaen T, M’bappé P, Boffa JJ, Khayat R, Mougenot B, Rossert J, et al. MPO-ANCA necrotizing glomerulonephritis related to rheumatoid arthritis. Am J Kidney Dis. 1998;32:E6.PubMedCrossRef
5.
Qarni M, Kohan DE. Pauci-immune necrotizing glomerulonephritis complicating rheumatoid arthritis. Clin Nephrol. 2000;54:54–8.PubMed
6.
Obayashi M, Uzu T, Harada T, Yamato M, Takahara K, Yamauchi A. Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis. Clin Exp Nephrol. 2003;7:275–8.PubMedCrossRef
7.
Yoshida A, Morozumi K, Suganuma T, Sugito K, Ikeda M, Oikawa T, et al. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis. Am J Nephrol. 1991;11:284–8.PubMedCrossRef
8.
Törnroth T, Skrifvars B. The development and resolution of glomerular basement membrane changes associated with subepithelial immune deposits. Am J Pathol. 1975;79:219–36.PubMed
9.
Nasr SH, Said SM, Valeri AM, Stokes MB, Masani NN, D’Agati VD, et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol. 2009;4:299–308.PubMedCrossRef
10.
Taniguchi Y, Yorioka N, Kumagai J, Ito T, Yamakido M, Taguchi T. Myeloperoxidase antineutrophil cytoplasmic antibody-positive necrotizing crescentic glomerulonephritis and membranous glomerulonephropathy. Clin Nephrol. 1999;52:253–5.PubMed
11.
Kanahara K, Yorioka N, Nakamura C, Kyuden Y, Ogata S, Taguchi T, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis with membranous nephropathy in remission. Intern Med. 1997;36:841–6.PubMedCrossRef
12.
Doulton TW, Tucker B, Reardon J, Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol. 2004;62:234–8.PubMed
13.
Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400–6.PubMedCrossRef
14.
Kemp E, Nielsen H, Petersen LJ, Gam AN, Dahlager J, Horn T, et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Clin Nephrol. 2001;55:87–8.PubMed
15.
Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin Rheumatol. 2008;27:261–4.PubMedCrossRef
16.
Simms R, Kipgen D, Dahill S, Marshall D, Rodger RS. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis. 2008;51:e11–4.PubMedCrossRef
17.
Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242–51.CrossRef
18.
Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol. 26(3) Suppl 49:S23–9.
19.
Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–9.PubMedCrossRef
20.
Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006;119:296–305.PubMedCrossRef
Metadata
Title
Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis
Authors
Kayoko Kaneko
Toshihiro Nanki
Tadashi Hosoya
Fumitaka Mizoguchi
Nobuyuki Miyasaka
Publication date
01-12-2010
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 6/2010
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-010-0333-3

Other articles of this Issue 6/2010

Modern Rheumatology 6/2010 Go to the issue

Letter

Male presenting with bilateral ankle arthritis? Request a chest X-ray!

Original Article

Common MEFV mutation analysis in 36 Iranian patients with familial Mediterranean fever: clinical and demographic significance

Acknowledgment

Acknowledgement

Rapid Communication

Time–concentration profile of serum etanercept in Japanese patients with rheumatoid arthritis after treatment discontinuation before orthopedic surgery

Original Article

Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis

Case Report

Organizing pneumonia in a patient with rheumatoid arthritis treated with etanercept
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits